Despite repeated requests by multiple Congresswomen and Administrators from the Essure Problems Facebook Group, FDA Commissioner Scott Gottlieb, refuses to allow any women affected by the device to attend meetings with the Congresswomen to discuss the safety of the device.
Bayer faces scrutiny regarding it post-market clinical trial on Essure due to conflicts of interest by several of its participating physicians. Three US Congresswomen seek a meeting with the FDA to discuss Essure and post-market studies regarding Class III medical devices.
Following a recent Essure Problems Rally in Washington DC, an emotional press conference and meetings with Admins from the Essure Problems Group, Congresswomen Rosa DeLauro, Louise Slaughter and Jan Schakowsky reach out to FDA regarding concerns over the safety of Essure.
The Essure Sisters, along with members of the Breast Implant Victim Advocacy Group, returned to Washington D.C. to rally and lobby Congress for the passage of H.R. 2164, The Medical Device Safety Act of 2017.
Much to the dismay of American women, Bayer has decided for 'commercial' reasons to cease selling Essure from the marketplace in every country except the United States. While the women are pleased by the fact that Essure is no longer being sold worldwide, they are angry and frustrated by the lack of action taken in the United States by both ...
Despite a worldwide decrease in demand for Essure, a three month suspension in Europe, a recall in Australia and the device being withdrawn from the market in Finland, the Netherlands, the UK and Canada; its still business as usual in America. FDA and America, wake the hell up.
Calling on all victims of a Class III medical device: A group of medical device advocates, led by the Essure Problems Group, will rally and lobby in Washington D.C. September 25-27th to gain support for the passage of the Medical Device Act of 2017.